Literature DB >> 16397408

Tumor-specific hyperactive low-molecular-weight cyclin E isoforms detection and characterization in non-metastatic colorectal tumors.

Irina Corin1, Marilena C Di Giacomo, Patrizia Lastella, Rosanna Bagnulo, Ginevra Guanti, Cristiano Simone.   

Abstract

PURPOSE: Several molecules involved in cancer biology have been studied as potential prognostic markers. Recently, overexpression of cyclin E and its low-molecular-weight (LMW) isoforms has been reported to be the most prominent prognostic marker in breast cancer, surpassing proliferation index, ploidy, and axillary nodal involvement. Furthermore, cyclin E and p53 are considered the main factors controlling the euploid equilibrium in human cells. We investigated the status of cyclin E and p53 in cell lines and tissue samples of colorectal cancer, one of the leading causes of death from a tumor in the Western world. EXPERIMENTAL
DESIGN: We analyzed colorectal cancer cells, from established cell lines and patient specimens, to determine the protein levels of cyclin E and p53, and to detect p53 and APC mutations, microsatellite and chromosome instability. In addition, we assessed the presence of cyclin E LMW isoforms and their enzymatic activity.
RESULTS: Colorectal cancer cells expressed hyperactive LMW forms both in vitro and in vivo. These tumor-specific isoforms are correlated to genomic instability even in p53-proficient cells, and represented a constant feature in the tumors analyzed.
CONCLUSIONS: In colorectal cancer, the formation of cyclin E LMW forms is an early event leading to DNA-damage checkpoint-independent proliferation. Collectively, our results provide evidence that evaluation of LMW forms could represent a novel tool in the molecular characterization of colorectal tumors aimed at identifying sensitive prognostic factors and uncovering subsets of high-risk patients within the traditional categories.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16397408     DOI: 10.4161/cbt.5.2.2356

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  15 in total

1.  Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification.

Authors:  Rozita Bagheri-Yarmand; Anna Biernacka; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.

Authors:  Joseph A Caruso; Mylinh T Duong; Jason P W Carey; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2018-09-07       Impact factor: 12.701

3.  Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells.

Authors:  Kimberly S Lucenay; Iman Doostan; Cansu Karakas; Tuyen Bui; Zhiyong Ding; Gordon B Mills; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2016-02-29       Impact factor: 12.701

4.  Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.

Authors:  Iman Doostan; Cansu Karakas; Mehrnoosh Kohansal; Kwang-Hui Low; Matthew J Ellis; John A Olson; Vera J Suman; Kelly K Hunt; Stacy L Moulder; Khandan Keyomarsi
Journal:  Clin Cancer Res       Date:  2017-09-25       Impact factor: 12.531

5.  Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.

Authors:  Kelly K Hunt; Khandan Keyomarsi; Cansu Karakas; Min Jin Ha; Anna Biernacka; Min Yi; Aysegul A Sahin; Opoku Adjapong; Gabriel N Hortobagyi; Melissa Bondy; Patricia Thompson; Kwok Leung Cheung; Ian O Ellis; Sarah Bacus; W Fraser Symmans; Kim-Anh Do
Journal:  Clin Cancer Res       Date:  2016-11-23       Impact factor: 12.531

6.  Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.

Authors:  Said Akli; Tuyen Bui; Hannah Wingate; Anna Biernacka; Stacy Moulder; Susan L Tucker; Kelly K Hunt; Khandan Keyomarsi
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

7.  A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.

Authors:  Zahi Mitri; Cansu Karakas; Caimiao Wei; Brian Briones; Holly Simmons; Nuhad Ibrahim; Ricardo Alvarez; James L Murray; Khandan Keyomarsi; Stacy Moulder
Journal:  Invest New Drugs       Date:  2015-05-07       Impact factor: 3.850

8.  AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.

Authors:  Mylin A Torres; Uma Raju; David Molkentine; Oliver Riesterer; Luka Milas; K Kian Ang
Journal:  Invest New Drugs       Date:  2010-02-02       Impact factor: 3.850

9.  Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer.

Authors:  Cansu Karakas; Anna Biernacka; Tuyen Bui; Aysegul A Sahin; Min Yi; Said Akli; Jolie Schafer; Angela Alexander; Opoku Adjapong; Kelly K Hunt; Khandan Keyomarsi
Journal:  Am J Pathol       Date:  2016-05-13       Impact factor: 4.307

10.  Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation.

Authors:  Nikki A Delk; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.